A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)
Andrew W. Hahn, Jad Chahoud, William Paul Skelton, Ying Yuan, Amado J. Zurita, C. Kovitz, Omar Alhalabi, Matthew T. Campbell, Eric Jonasch, John K. Lin, Meera Desai, Michael Keith San Diego. Santos, Hyunsoo Hwang, Paul G. Corn, Pavlos Msaouel, Nizar M. Tannir
Topics & Concepts
LenvatinibMedicineCabozantinibEverolimusOncologyInternal medicinePD-L1NivolumabRandomized controlled trialImmune checkpointClinical trialTyrosine-kinase inhibitorPhases of clinical researchDiscovery and development of mTOR inhibitorsPembrolizumabMetastatic melanomaRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments